Synta Pharmaceuticals Corp. Share Price Nasdaq
Equities
US87162T2069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 7.35Cr 612.97Cr | Sales 2025 * | 36Cr 3.04TCr | Capitalization | 586.83Cr 49TCr |
---|---|---|---|---|---|
Net income 2024 * | -58Cr -4.86TCr | Net income 2025 * | -40Cr -3.36TCr | EV / Sales 2024 * | 70.4 x |
Net cash position 2024 * | 69Cr 5.78TCr | Net cash position 2025 * | 29Cr 2.43TCr | EV / Sales 2025 * | 15.3 x |
P/E ratio 2024 * |
-9.95
x | P/E ratio 2025 * |
-15.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.81% |
Latest transcript on Synta Pharmaceuticals Corp.
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 01/11/01 |
William Sibold
CEO | Chief Executive Officer | 57 | 08/23/08 |
Rebecca Taub
FOU | Founder | 71 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Craves
FOU | Founder | 78 | 01/11/01 |
Julian Baker
CHM | Chairman | 57 | 15/23/15 |
Ken Bate
BRD | Director/Board Member | 73 | 22/16/22 |
1st Jan change | Capi. | |
---|---|---|
+16.71% | 12TCr | |
+20.03% | 12TCr | |
+21.22% | 2.66TCr | |
-23.18% | 1.99TCr | |
-17.47% | 1.63TCr | |
-45.95% | 1.55TCr | |
-18.22% | 1.55TCr | |
+59.39% | 1.48TCr | |
+3.30% | 1.37TCr |